Media ReleasesNoxopharm

View All Noxopharm News


Noxopharm Announces Positive Data from CEP-1 Study of Veyonda

• Final CEP-1 data confirm tolerability of Veyonda alone and in combination with carboplatin

• Halt in progression of cancer growth in 50% of patients

• Study provides proof-of-concept for well-tolerated chemotherapy with meaningful survival benefit

SYDNEY, November 29, 2018, Noxopharm (ASX:NOX) announces the final results from its Phase 1b CEP-1 trial evaluating its lead immuno-oncology/radio-enhancer drug candidate, Veyonda, in combination with low-dose carboplatin in late-stage metastatic solid cancers.


For further information please download PDF attached:
Download this document